David Reinhardt, DO
Orthopaedic Surgery · Southampton, PANPI 1548255169
Payments from drug & device makers
Across 86 payments — averaging $213.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medacta USA, Inc.$12K
- Smith+Nephew$4K
- Arthrex$974
- Paladin Technology Solutions$715
- Stryker$476
- Fidia Pharma USA Inc.$280
- plus $532 from 11 others
What the payments were for
- Travel & lodging$14,45479%
- Food & beverage$3,73320%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medacta USA, Inc. | 16 | $11,582 |
| Smith+Nephew | 21 | $3,785 |
| Arthrex | 10 | $974 |
| Paladin Technology Solutions | 5 | $715 |
| Stryker | 7 | $476 |
| Fidia Pharma USA Inc. | 8 | $280 |
| Zimmer Biomet | 3 | $150 |
| Catalyst Orthoscience | 1 | $74 |
| Heraeus Medical, LLC. | 5 | $57 |
| Liberty Surgical Inc. | 1 | $54 |
| Pacira Therapeutics, Inc. | 2 | $45 |
| Heron Therapeutics, Inc. | 2 | $36 |
| Nalu Medical, Inc. | 1 | $35 |
| Treace Medical Concepts, Inc. | 1 | $26 |
| Solventum Corporation | 1 | $24 |
| Johnson & Johnson | 1 | $18 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMISTEM$6,797
- GMK SPHERE$3,561
- Journey II$3,154
- Legion Revision$1,878
- OR3O Dual Mobility$1,847
- RI.HIP NAVIGATION$1,553
- JOURNEY$1,553
- REAL INTELLIGENCE$907
- PRIMARY SHOULDER$702
- Journey II XR$325
- POLARSTEM$325
- VISIONAIRE$206
- RICHPLAT ORTHO PRP SYSTEM$157
- Hymovis$157
- INSPACE$136
- EFFICIENCY$113
How this compares
$18,344 in reported general payments places this provider in the 75th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $1,508 |
| Diclofenac Sodium | 70 | $614 |
| Meloxicam | 148 | $583 |
| Oxycodone Hcl | 93 | $300 |
| Etodolac | 19 | $261 |
| Tramadol Hcl | 117 | $250 |
| Ondansetron OdtOndansetron | 27 | $247 |
| Gabapentin | 33 | $165 |
| Methylprednisolone | 33 | $164 |
| Clindamycin Hcl | 42 | $151 |
| Cephalexin | 72 | $136 |
| Ondansetron Hcl | 53 | $120 |
| Celecoxib | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Southampton
- William HozackBensalem$10.6M
- Jess LonnerBryn Mawr$8.1M
- Gerald WilliamsBryn Mawr$6.8M
- Mark LazarusBensalem$6.4M
- John FenlinPhiladelphia$5.9M
- Peter SharkeyKing Of Prussia$5.7M
- Selene ParekhBensalem$4.9M
- Alexander VaccaroPhiladelphia$4.5M
- Joseph AbboudPhiladelphia$4.1M
- Jonathan GarinoMalvern$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.